Valentina Rossi: Addressing Inflammation and Immune Mechanisms in Cardiomyopathy Management
Valentina Rossi, Specialist in Cardiology and Internal Medicine at The University Hospital Zurich, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“My first manuscript within my PhD program at the Maastricht University about Immune-Mediated Cardiomyopathies and Their Impact on Long-Term Outcomes has been just published in the European Journal of Heart Failure! Key findings include:
- Higher Risk of Adverse Events: Patients with ID-CMP face a significantly higher risk of major adverse cardiovascular events (MACE), including cardiac mortality, heart failure hospitalization, and life-threatening arrhythmias, compared to non-immune DCM patients.
- Inflammation as a Key Factor: Persistent myocardial inflammation, evidenced by elevated immune cell counts (CD3+, CD45+, CD68+), is linked to worse outcomes, independent of genetic factors or left ventricular ejection fraction (LVEF) recovery.
- Similar LVEF Trajectories: Despite worse outcomes, ID-CMP patients show comparable long-term LVEF recovery to nonID-CMP patients, suggesting factors beyond systolic function drive disease progression.
- Validation Across Cohorts: Findings were confirmed in an external validation cohort, highlighting the need for tailored management and enhanced cardiovascular surveillance for ID-CMP patients.
This study underscores the importance of addressing inflammation and immune mechanisms in cardiomyopathy management.”
Title: Clinical characteristics and outcomes of cardiomyopathies related to immune-mediated diseases
Authors: Valentina A Rossi, Maurits A Sikking, Alessandro Folgheraiter, Carola Pio Loco, Fernando Dominguez, Bastien S C Nihant, Sophie L V M Stroeks, Michiel T H M Henkens, Nerea Mora-Ayestarán, Noemí Ramos-López, Gianfranco Sinagra, Pablo Garcia-Pavia, Frank Ruschitzka, Marco Merlo, Job A J Verdonschot, Stephane R B Heymans
Read the Full Article on European Heart Journal.

Stay updated on all scientific advances with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis